NCT03858894 - Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions

Primary Open-angle Glaucoma and Ocular Hypertension

Interventions

DRUG

DE-117 Ophthalmic Solution QD

DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye

DRUG

DE-117 Ophthalmic Solution BID

DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye

Trial Locations (13)

11563

Ophthalmic Consultants of Long Island, Lynbrook

16066

Scott & Christie and Associates PC, Cranberry Township

21078

Seidenberg Protzko Eye Associates, Havre de Grace

32204

Levenson Eye Associates, Jacksonville

34613

Hernando Eye Institute, Brooksville

37205

Advanced Vision Research, Nashville

37803

University Eye Specialist, Maryville

44115

Abrams Eye Center, Cleveland

45242

Apex Eye Clinical Research, LLC, Cincinnati

63128

Tekwani Vision Center, St Louis

90013

East West Eye Institute, Los Angeles

06810

Danbury Eye Specialist, Danbury

08361

Eye Associates/SurgiCenter of Vineland, Vineland

All Listed Sponsors

lead

Santen Inc.

INDUSTRY